Plural Benzene Rings Patents (Class 514/721)
-
Patent number: 8669292Abstract: The invention provides compositions and formulations comprising catechol and/or acetogenins and various combinations thereof; including various combinations with other ingredients including botanical preparations containing acetogenin, an extract of green tea or a therapeutically active flavanoid contained in green tea; and one or more quinones. The invention includes a pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and optionally, an acetogenin and an extract of green tea. The compositions and formulations demonstrate positive effects against a broad variety of cancer, autoimmune diseases, viruses and provides antioxidant protection against peroxyl hydrophilic, peroxyl lipophilic, hydroxyl, peroxynitrite and super oxide radicals. The compositions and formulations can be used for nutritional and nutraceutical uses, and used as dietary supplements.Type: GrantFiled: April 17, 2009Date of Patent: March 11, 2014Assignee: Orion Therapeutics, LLCInventor: Jerome Godin
-
Patent number: 8658838Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.Type: GrantFiled: December 20, 2012Date of Patent: February 25, 2014Assignee: Unigen, Inc.Inventors: Sandip K. Nandy, Jiyun Liu, Alexandre Mikhailovitch Nesterov, Carmen Hertel, Abeysinghe A. Padmapriya
-
Patent number: 8653053Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.Type: GrantFiled: June 26, 2012Date of Patent: February 18, 2014Assignee: Galderma S.A.Inventors: Nancy Puglia, Jerry Roth, Rosario Ramirez
-
Publication number: 20140044766Abstract: The present invention relates to a method for the antimicrobial protection of a plane or non-plane surface of a material object, i.e. other than a human or animal body, characterized in that the face termed the inner face of a self-adhesive plastics film (1) coated on its face termed the inner face with a layer of adhesive (2) is applied against the surface of the object, said film being constituted by plasticized PVC comprising a polymeric plasticizer, said film being flexible and manually stretchable and capable of following the contour of a said surface, having an elongation at break of more than 50% and an ultimate tensile strength of less than 6000 N/m, and said film incorporating in its material or comprising on its surface termed the outer surface an antimicrobial agent rendering the outer surface of said film active against microbes.Type: ApplicationFiled: August 7, 2013Publication date: February 13, 2014Inventors: Christophe BAUDRION, Frederic MASSON, Michel MATEU
-
Publication number: 20140005616Abstract: Single layer and multi-layer anti-microbial wound care fabrics, gloves, sleeves, anklets, socks, finger cots, masks, and similar wound care articles are disclosed.Type: ApplicationFiled: June 27, 2013Publication date: January 2, 2014Applicant: Ansell LimitedInventors: JEFFREY MORELAND, ROGER EUGENE HUCKFELDT, DION ROSS, ERIC THOMPSON, JAMIE ASHWORTH, MICHAEL ZEDALIS, ANTHONY B. LOPEZ
-
Patent number: 8609736Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.Type: GrantFiled: June 4, 2008Date of Patent: December 17, 2013Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Aviv Gazit, Shimon Slavin, Esther Priel, Sara Yitzchak
-
Publication number: 20130331413Abstract: Disclosed are compositions and methods for treating and/or preventing infections in mammals, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are kits that include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Erik DE LEEUW, Alexander D. MACKERELL, JR.
-
Patent number: 8604087Abstract: Disclosed is a composition for treating or preventing amyloid-related diseases including 4-O-methylhonokiol as an active ingredient. More specifically, a pharmaceutical composition including 4-O-methylhonokiol, which is effective for treating or preventing amyloid-related diseases such as Alzheimer's disease, cognitive disorder, defective memory, amyloidosis, etc. is disclosed. The inventors of the present disclosure have found out for the first time that 4-O-methylhonokiol inhibits the production of ?-amyloid. It has been confirmed to be useful in treating or preventing amyloid-related diseases. Through animal tests including water maze test and passive avoidance test on mice, 4-O-methylhonokiol has been confirmed to be effective for amyloid-related diseases such as Alzheimer's disease, defective memory, cognitive disorder, and the like.Type: GrantFiled: September 25, 2009Date of Patent: December 10, 2013Assignee: Bioland Ltd.Inventors: Ki Ho Kim, Ki Soo Kim, Young Heui Kim, Jin Guk Kim, Kyoung Tae Kim, Chang Sung Han, Sang iL Lee
-
Publication number: 20130324615Abstract: A biodegradation suppression system may include an anti-microbial agent, wherein the anti-microbial agent is effective to suppress biodegradation of ignitable liquid residues within a forensic sample. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of ignitable liquid residues within a forensic sample for a period of time. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of gasoline, wherein the solution is effective to allow for identification of at least one component of gasoline within the forensic sample.Type: ApplicationFiled: February 23, 2012Publication date: December 5, 2013Applicant: Indiana University Research and Technology CorporationInventor: John Goodpaster
-
Patent number: 8592488Abstract: Diarylalkanes having the following structure: wherein Ar1, Ar2, R6, R7 and n are as defined herein are provided. The disclosed compounds find utility as inhibitors of binuclear enzymes. Methods for inhibiting binuclear enzymes as well as methods and compositions for preventing and treating diseases and conditions associated with binuclear enzymes are also provided.Type: GrantFiled: June 11, 2010Date of Patent: November 26, 2013Assignee: Unigen, Inc.Inventors: Qi Jia, Ji-Fu Zhao
-
Publication number: 20130303531Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: May 14, 2012Publication date: November 14, 2013Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20130303541Abstract: The present invention discloses an aryloxy dihalopropenyl ether compound with the structure shown as general formula (I), of which the group definitions can be seen in the specification. The present invention also discloses the use of the compound with general formula (I) as an insecticide in the agricultural field and an insecticidal composition using the compound with general formula (I) as an active component.Type: ApplicationFiled: March 28, 2012Publication date: November 14, 2013Applicants: Shenyang Research Institute Of Chemical Industry Co., Ltd., SINOCHEM CORPORATIONInventors: Changling Liu, Jichun Yang, Xiuhui Chang, Miao Li, KeKe Li, Qiao Wu, Yuquan Song
-
Publication number: 20130280313Abstract: Provided is a matrix type antimicrobial vehicle, including: a matrix layer comprising an antimicrobial agent and an adhesive; an antimicrobial agent-releasing layer formed on one surface of the matrix layer; and a release liner formed on the other surface of the matrix layer, and a method for preparing the same. The matrix type antimicrobial vehicle is incorporated into a package having a medical kit so that the antimicrobial agent is released to the surface of medical kit or package continuously. Therefore, it is possible for the surface of the medical kit or package to maintain a constant concentration of antimicrobial agent continuously even when the medical kit or package is stored for a long time.Type: ApplicationFiled: December 27, 2011Publication date: October 24, 2013Applicant: SAMYANG BIOPHARMACEUTICALS CORPORATIONInventors: Hye Sung Yoon, Hyun Kyoon Kim, Wang Soo Shin, Sun Woo Kim
-
Publication number: 20130267474Abstract: The present invention describes phytochemicals present in maple syrup and maple tree extracts by butanol, ethyl acetate and methanol. Novel compounds are isolated from maple syrups, including one compound Quebecol generated in the maple syrup manufacturing process. Also described are digesting extract of maple syrup. The phytochemicals may be used for the treatment or prevention of cancers, metabolic syndromes, diabetes, microorganism infections and/or antioxidants.Type: ApplicationFiled: August 19, 2011Publication date: October 10, 2013Applicants: UNIVERSITY OF RHODE ISLAND, FÉDÉRATION DES PRODUCTEURS ACÉRICOLES DU QUÉBECInventors: Navindra P. Seeram, Liya Li, Geneviéve Béland, Julie Barbeau
-
Publication number: 20130261146Abstract: A pharmaceutical composition for stimulating nitric oxide production in mammalian cells, the pharmaceutical composition including at least one compound selected from a group consisting of: 2,3-dihydroxypropyl oleate; bis(m-phenoxyphenyl) ether; 6-acetyl-5,6,6a,7-tetrahydro-4H-dibezo(de,g)quinoline; and (+)-N-(p-(2-methylbutoxy)benzylidene)-4-(2-methylbutyl)aniline.Type: ApplicationFiled: December 9, 2010Publication date: October 3, 2013Applicant: The Research Foundation of State University of New YorkInventors: George B. Stefano, Wei Zhu, Kirk Mantione, Richard M. Kream
-
Publication number: 20130255061Abstract: An antimicrobial composition, generally comprising a biocidal agent, such as chlorhexidine gluconate, a lubricant, such as a modified siloxane, and a solvent, such as an alcohol and/or water. The biocidal agent acts as a highly effective biocide while the lubricant reduces friction between various components of a medical device during assembly. The antimicrobial composition may be applied to an internal component of the medical device prior to assembly. The process of assembling the medical device results in antimicrobial composition being distributed to various internal structures and geometries of the medical device as the coated, internal component is assembled into the interior of the medical device. Air is then used to further distribute excess antimicrobial agent to the remaining surfaces downstream from the installed, internal component. In some embodiments, additional air is passed through the assembled medical device to assist in removing the carrier solvent from the medical device via evaporation.Type: ApplicationFiled: April 3, 2012Publication date: October 3, 2013Applicant: BECTON, DICKINSON AND COMPANYInventors: Jonathan Karl Burkholz, Minh Quang Hoang
-
Publication number: 20130245129Abstract: This invention provides compound having a structure of Formula I or Formula II Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: April 19, 2013Publication date: September 19, 2013Applicants: The University of British Columbia, British Columbia Cancer Agency BranchInventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc
-
Publication number: 20130236499Abstract: Novel semi-crystalline, segmented copolymers of lactide and epsilon-caprolactone exhibiting long term absorption characteristics are disclosed. The novel polymer compositions are useful for long term absorbable meshes, surgical sutures, especially monofilament sutures, and other medical devices.Type: ApplicationFiled: March 12, 2012Publication date: September 12, 2013Inventors: Sasa Andjelic, Dennis D. Jamiolkowski
-
Publication number: 20130231396Abstract: The invention relates to novel polyphenol-quinonoid polymer derivatives, methods of synthesizing, compositions and uses thereof. In particular, the invention relates to polyphenol-quinonoid polymer derivatives useful in the treatment of viral infections, notably conditions caused by retroviruses such as human immunodeficiency virus (HIV).Type: ApplicationFiled: November 3, 2011Publication date: September 5, 2013Applicant: ABRA PHARMACEUTICAL SÁRLInventor: Aldo Bruccoleri
-
Publication number: 20130225517Abstract: The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.Type: ApplicationFiled: February 22, 2013Publication date: August 29, 2013Applicant: University of Iowa Research FoundationInventor: University of Iowa Research Foundation
-
Publication number: 20130210928Abstract: The present invention provides a novel biphenyl compound or pharmaceutically acceptable salts thereof, methods for preparing the same, and pharmaceutical compositions for preventing or treating diabetic complications containing the same as an active ingredient. Novel biphenyl compounds, according to the present invention, effectively suppress generation activity of advanced glycation end products, which cause diabetic complications and are a criterion for evaluating the effectiveness of a treating agent for diabetic complications, and show an excellent therapeutic effect on retina blood vessels, increased occludin, and decreased angiogenic growth factor in actual diabetic retinopathy induced retina. Thus, novel biphenyl compounds according to the present invention can be used effectively as an active ingredient in compositions for preventing or treating diabetic complications such as diabetic retinopathy.Type: ApplicationFiled: August 11, 2011Publication date: August 15, 2013Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINEInventors: Jin Sook Kim, Young Sook Kim, Jung Hyun Kim, Eun Jin Shon, Ki Mo Kim, Chan-sik Kim, Dong Ho Jung, Yun Mi Lee, Kyu Hyung Jo, Ohn Soon Kim, Nam-Hee Yoo
-
Publication number: 20130203688Abstract: The present document describes a nutraceutical or cosmeceutical composition for the prophylaxis of an ailment comprising a therapeutically effective amount of a sugar plant syrup filtration residue in association with a pharmaceutically acceptable carrier. The present document also describes a nutraceutical or cosmeceutical composition for improving health condition of skin. The present document describes a method of producing a sugar plant syrup-derived product; wherein the improvement is characterized in the step of: collecting a sugar plant syrup residue during the production of sugar or syrup to produce a syrup-derived by-product.Type: ApplicationFiled: August 19, 2011Publication date: August 8, 2013Applicant: FÉDÉRATION DES PRODUCTEURS ACÉRI-COLES DU QUÉBECInventors: Julie Barbeau, Geneviève Béland
-
Patent number: 8501820Abstract: A pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and, optionally, an acetogenin. The formulation demonstrates positive effects against cancer, autoimmune disease, viruses and provides antioxidant protection against peroxyl, hydroxyl and super oxide radicals.Type: GrantFiled: May 30, 2008Date of Patent: August 6, 2013Assignee: Orion Therapeutics, L.L.C.Inventor: Jerome Godin
-
Publication number: 20130157930Abstract: The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by as well as a variety of uses to coat, form or comprise medical devices, combination medical devices and pharmaceutical compositions, including sustained release formulations.Type: ApplicationFiled: February 13, 2013Publication date: June 20, 2013Applicant: TYRX, INC.Inventor: TYRX, INC.
-
Publication number: 20130131167Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.Type: ApplicationFiled: January 6, 2011Publication date: May 23, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Publication number: 20130131182Abstract: The present invention relates to chemical total synthesis methods of six novel protein tyrosine phosphatase-1B (PTP1B) inhibitors and application of the inhibitors in the preparation of medicaments for treating type 2 diabetes mellitus (T2DM). The PTP1B inhibitors use one or more of the six compounds represented by the structural formulae 1, 2, 3, 4, 5 and 6, as active components. The compounds can enhance the sensitivity of an insulin receptor by inhibiting the activity of PTP1B, thereby having a favorable therapeutic effect on insulin-resistant T2DM.Type: ApplicationFiled: July 7, 2011Publication date: May 23, 2013Applicant: INSTITUTE OF OCEANOLOGY, CHINESE ACADEMY OF SCIENCESInventors: Dayong Shi, Shuju Guo, Xiao Fan, Weishen Lu, Yongchao Cui
-
Publication number: 20130109758Abstract: This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: January 6, 2011Publication date: May 2, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Publication number: 20130101687Abstract: Insecticidal compositions have at least one active agent and at least one insecticide. The active agent can include perilla oil, a component found in perilla oil, or a perillaldehyde or carvone analog. The insecticide can include a pyrethrum, pyrethrin, pyrethroid, neonicotinoid, chlofenapyr, ethiprole, sulfoxoflor, carbamate, organophosphate, or organochlorine. Methods for controlling insects include contacting an insect with an effective amount of a composition described in this specification. Modified plants that produce an active agent can be contacted with an insecticide.Type: ApplicationFiled: July 13, 2012Publication date: April 25, 2013Inventors: Michael Dean Willis, Marie Elizabeth Saunders, Darryl Ramoutar, Joanna Maria Szymczyk, Frances Nita Krenick, Andrea Rohrbacher
-
Patent number: 8415393Abstract: The present invention provides methods for the design and identification of novel antimicrobial compounds, and provides antimicrobial compounds identified using these methods. These antimicrobial compounds inhibit the binding of a prokaryotic single-stranded DNA binding protein to a polypeptide that binds to the prokaryotic single-stranded DNA binding protein. In some examples, the prokaryotic single-stranded DNA binding protein is prokaryotic Exonuclease I. In one embodiment, the antimicrobial compound has the structure wherein Y is selected from the group consisting of CH2, O, and NH, R1 is selected from the group consisting of H, F, Cl, Br, and I, R2 is selected from the group consisting of H and CF3, R3 is selected from the group consisting of H and CO2H, R4 is selected from the group consisting of H and OH, and R5 is selected from the group consisting of H, alkoxy, and NO2.Type: GrantFiled: May 21, 2008Date of Patent: April 9, 2013Assignee: Wisconsin Alumni Research FoundationInventors: James L. Keck, Douglas A. Bernstein
-
Publication number: 20130065850Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: ApplicationFiled: April 3, 2012Publication date: March 14, 2013Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
-
Publication number: 20130053335Abstract: Disclosed is a composition comprising a derivative of NDGA and 7-hydroxystaurosporine. The composition can be in a unit dose form or kit. Also disclosed are methods for achieving cytotoxicity, particularly of rapidly dividing cells such as cancer, by administering a composition of the invention. In various embodiments of the invention subjects with cancer achieve prolonged survival and/or diminution in the size of their malignancies and cancer metastasis.Type: ApplicationFiled: February 22, 2011Publication date: February 28, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Ru Chih C. Huang, Kotohiko Kimura
-
Publication number: 20130052248Abstract: An item of clothing (10) for daily pharmacological treatment of a fungal infection, comprising: a textile material (20) to manage moisture when the item of clothing (10) is worn; microcapsules (30) grafted on the textile material (20); and antifungal agents encapsulated within the microcapsules (30) to pharmacologically treat the fungal infection when released from the microcapsules (30).Type: ApplicationFiled: August 26, 2011Publication date: February 28, 2013Inventors: Marcus Chun Wah YUEN, Joanne Yiu Wan YIP, Kevin CHEUK, Chi Wai KAN, Shuk Yan CHENG
-
Publication number: 20130045204Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, and wherein at least one of R1, R2, R3, R4 or R5 is F, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: August 17, 2012Publication date: February 21, 2013Applicants: The University of British Columbia, British Columbia Cancer Agency BranchInventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar, Carmen Adriana Banuelos, Nasrin Mawji, Jun Wang
-
Patent number: 8362305Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.Type: GrantFiled: July 21, 2009Date of Patent: January 29, 2013Assignee: Unigen, Inc.Inventors: Sandip K. Nandy, Jiyun Liu, Alexandre Mikhailovitch Nesterov, Carmen Hertel, Abeysinghe A. Padmapriya
-
Patent number: 8361970Abstract: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.Type: GrantFiled: November 19, 2009Date of Patent: January 29, 2013Assignees: University of South Florida, Yale UniversityInventors: Said M. Sebti, Andrew D. Hamilton
-
Publication number: 20130018026Abstract: The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Inventor: Keith R. Latham
-
Publication number: 20130017163Abstract: The present invention provides compositions and methods of their administration for the protection of cells and tissues from damage caused by FROS in the body of an individual. Compositions comprising halogenated phenol compounds are provided that scavenge or consume FROS in the body. These FROS scavenging compounds may not only protect cells and tissues from damage, but also treat disease and/or alleviate the symptoms of disease associated with high FROS levels. Sunscreen compositions comprising FROS-scavenging compounds of the present invention are further provided to reduce the damaging effects of sunlight on the skin of an individual.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Inventor: Keith R. Latham
-
Publication number: 20130011490Abstract: This invention relates to a “high lower alcohol content” (>40% v/v of a C1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a silicone-based surfactant of at least 0.001% by weight to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and moisturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.Type: ApplicationFiled: September 10, 2012Publication date: January 10, 2013Applicant: DEB WORLDWIDE HEALTHCARE INC.Inventors: Maria Teresa Fernandez de Castro, Bruce Michael Koivisto, Francisco Munoz
-
Patent number: 8318699Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.Type: GrantFiled: January 31, 2006Date of Patent: November 27, 2012Assignees: The Trustees Of The University Of Pennsylvania, Cephalon, Inc.Inventors: Mark I Greene, Ramachandran Murali, Xin Cheng, Raphael Ottenbrite, Yingxin Xiao
-
Publication number: 20120288566Abstract: The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity.Type: ApplicationFiled: October 5, 2010Publication date: November 15, 2012Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Michael Friedman, Doron Steinberg, Irith Gati
-
Publication number: 20120277772Abstract: The invention relates to a treated HPPE yarn characterized in that the treated HPPE yarn comprises: a porous polyolefin layer that adheres to a surface of a HPPE yarn and covers at least partly the surface of the HPPE yarn; a composition comprising an active agent and which composition is at least partially absorbed within the porous polyolefin layer. The invention further relates to an article comprising the treated HPPE yarn, a device comprising the treated HPPE yarn or the article. The invention also relates to a process for preparing the treated HPPE yarn or treated HPPE yarn structure or treated HPPE yarn configuration and use of the treated HPPE yarn or an article or a device comprising the treated HPPE yarn for automotive applications, marine applications, aerospace applications, medical applications, defense applications, sports/recreational applications, architectural applications, clothing applications, bottling applications, machinery applications.Type: ApplicationFiled: August 5, 2010Publication date: November 1, 2012Applicant: DSM IP ASSETS B.V.Inventors: Gerardus Aben, Edith Elizabeth Van Den Bosch, Claudia Maria Vaz
-
Publication number: 20120255502Abstract: A method of treatment and a package that is designed to accomplish this. The package provides the pet owner with a pack containing individual doses of topically applied medications pre-packaged with an oral taste treat. The topically applied medication contains at least one pharmaceutically active ingredient selected from the group of chemical families comprising phenylpyrazoles, macrocyclic lactones, neonicotinoids, synthetic pyrethroids, insect growth regulators, amidines, semicarbazones, spinosyns, octadepsipeptides, and pyrazinoisoquinolines, or any combination thereof. The treat can be administered either before the topically applied treatment is given so as to relax and distract the pet, or after the treatment is given so as to reward the pet and help it forget the stress of treatment. The treat can also be shaped to signify the type of animal to be treated.Type: ApplicationFiled: March 29, 2012Publication date: October 11, 2012Applicant: ALLEVA ANIMAL HEALTH LIMITEDInventor: Robert HOLMES
-
Patent number: 8273757Abstract: The present invention is a novel analgesic combination and its use. It is classified to be an invention in the field of medicine and technology. The purpose of this invention is to solve the problem that existing analgesics does not effectively attenuate pain or produces serious side-effects in clinic. The ingredients of the analgesic combination include ketanserin and propranolol. This combination is used to make a drug to treat pain. Because the ingredients of the analgesic combination target peripheral receptors, the unwanted effects could be only minimal. The big advantage of this combination is that each of the ingredients acts on the different receptors producing the synergizing analgesic. Therefore, the analgesia that the combination produces is remarkable and the effective doses are low.Type: GrantFiled: August 30, 2010Date of Patent: September 25, 2012Inventor: Yanguo Hong
-
Publication number: 20120220454Abstract: Coating compositions and methods of use, allowing for improved water and/or nutrient usage by seeds, plants, shrubs, and vegetation, among others, are disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 30, 2012Applicant: RHODIA OPERATIONSInventors: Zhiyun Chen, Jean-Christophe Castaing, PengFei JI, Galder Cristobal
-
Patent number: 8247395Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.Type: GrantFiled: March 29, 2011Date of Patent: August 21, 2012Assignee: Galderma S.A.Inventors: Nancy Puglia, Jerry Roth, Rosario Ramirez
-
Publication number: 20120195950Abstract: A laundry additive such as a fabric dryer sheet formed of a flexible substrate contains an insecticidally effective amount of an insecticide, preferably a pyrethrum, in an amount between about 0.05 and about 10 grams per square foot. Alternatively, the insecticide may be included as a component in a rinse-cycle laundry additive. Such laundry additives are appropriate for use by institutions such as hotels, cruise ships, and nursing homes, hospitals, and shelters in the prevention and control of bed bugs.Type: ApplicationFiled: April 11, 2012Publication date: August 2, 2012Inventor: Stevan L. Troutman
-
Publication number: 20120148651Abstract: According to one embodiment, a coagulant comprising calcium nitrate and an antimicrobial agent is disclosed. The coagulant may be used in the molding process to releasably bond the substrate material to the mold and to bond to the antimicrobial to the substrate material.Type: ApplicationFiled: December 10, 2010Publication date: June 14, 2012Applicant: MEDLINE INDUSTRIES INC.Inventors: Samuel T. Amdur, Min Yao
-
Patent number: 8198326Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including an antiseptic such as halogenated phenols, bisphenols, diphenyl ethers, anilides and derivatives thereof, and combinations thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).Type: GrantFiled: September 7, 2004Date of Patent: June 12, 2012Assignee: 3M Innovative Properties CompanyInventor: Matthew T. Scholz
-
Patent number: 8187825Abstract: It is an object of the present invention to provide: a novel thiol-detecting reagent, which can be used in vivo and which solves the problem regarding the generation of background fluorescence due to hydrolysis; and a method for detecting thiol using the aforementioned reagent. The present invention provides a compound represented by the following formula (1): wherein each R2 independently represents an alkyl group containing 1 to 6 carbon atoms, a halogen atom, or a hydrogen atom.Type: GrantFiled: January 30, 2009Date of Patent: May 29, 2012Assignee: RikenInventors: Hiroshi Abe, Yoshihiro Ito, Aya Shibata, Mika Ito
-
Publication number: 20120128793Abstract: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device.Type: ApplicationFiled: January 24, 2012Publication date: May 24, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Kathleen M. Miller, Gregory T. Sydney, Kurt Geitz, Peter L. Dayton, Ronald A. Sahatjian